Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
- Conditions
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT05112965
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
🇨🇳Tianjin Cancer Hospital, Tianjin, China
🇨🇳Zhongshan Hospital Fudan University, Shanghai, China
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 27
- Registration Number
- NCT05104788
- Locations
- 🇨🇳
BeijingCancerH, Beijing, China
STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Synthekine
- Target Recruit Count
- 202
- Registration Number
- NCT05098132
- Locations
- 🇺🇸
Northwell Health, Lake Success, New York, United States
🇺🇸NYU Langone Health, New York, New York, United States
🇺🇸The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
- Conditions
- Interventions
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 82
- Registration Number
- NCT05096663
- Locations
- 🇺🇸
Kaiser Permanente West Los Angeles, Los Angeles, California, United States
🇺🇸Illinois CancerCare-Princeton, Princeton, Illinois, United States
🇺🇸UPMC-Mercy Hospital, Pittsburgh, Pennsylvania, United States
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 830
- Registration Number
- NCT05067283
- Locations
- 🇺🇸
Moffitt Cancer Center ( Site 0261), Tampa, Florida, United States
🇺🇸START Midwest ( Site 0267), Grand Rapids, Michigan, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center ( Site 0260), Hackensack, New Jersey, United States
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
- Conditions
- Interventions
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 67
- Registration Number
- NCT05059522
- Locations
- 🇺🇸
Highlands Oncology Group, PA, Springdale, Arkansas, United States
🇷🇺Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Dispensary", Omsk, Omskaya Oblast', Russian Federation
🇺🇸MSK Monmouth, Middletown, New Jersey, United States
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Hunan Province Tumor Hospital
- Target Recruit Count
- 12000
- Registration Number
- NCT05055908
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
- Conditions
- Interventions
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT05048797
- Locations
- 🇹🇷
Research Site, Çankaya, Turkey
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18)
- Conditions
- Interventions
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 72
- Registration Number
- NCT05017012
- Locations
- 🇨🇱
James Lind Centro de Investigación del Cáncer ( Site 0102), Temuco, Araucania, Chile
🇨🇱FALP-UIDO ( Site 0101), Santiago, Region M. De Santiago, Chile
🇿🇦Cancercare Rondebosch Oncology-Clinical trials ( Site 0055), Rondebosch, Western Cape, South Africa
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Fundación GECP
- Target Recruit Count
- 71
- Registration Number
- NCT05012254
- Locations
- 🇪🇸
Hospital Provincial de Castellón, Castelló de la Plana, Castellon, Spain
🇪🇸Hospitalario Universitario A Coruña, A Coruña, La Coruña, Spain
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.